tradingkey.logo
tradingkey.logo
Search

vTv Therapeutics Inc

VTVT
Add to Watchlist
35.400USD
+0.350+1.00%
Close 07/02, 13:00ETQuotes delayed by 15 min
139.44MMarket Cap
LossP/E TTM

TradingKey Stock Score of vTv Therapeutics Inc

Currency: USD Updated: 2026-07-02

Key Insights

vTv Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 59 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 54.80.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

vTv Therapeutics Inc's Score

Industry at a Glance

Industry Ranking
59 / 387
Overall Ranking
149 / 4565
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

vTv Therapeutics Inc Highlights

StrengthsRisks
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -73.17, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.41M shares, increasing 11.70% quarter-over-quarter.

Analyst Rating

Based on 5 analysts
Buy
Current Rating
54.800
Target Price
+51.09%
Upside Space

FAQs

How does TradingKey generate the Stock Score of vTv Therapeutics Inc?

The TradingKey Stock Score provides a comprehensive assessment of vTv Therapeutics Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of vTv Therapeutics Inc’s performance and outlook.

How do we generate the financial health score of vTv Therapeutics Inc?

To generate the financial health score of vTv Therapeutics Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects vTv Therapeutics Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of vTv Therapeutics Inc.

How do we generate the company valuation score of vTv Therapeutics Inc?

To generate the company valuation score of vTv Therapeutics Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare vTv Therapeutics Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of vTv Therapeutics Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of vTv Therapeutics Inc.

How do we generate the earnings forecast score of vTv Therapeutics Inc?

To calculate the earnings forecast score of vTv Therapeutics Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on vTv Therapeutics Inc’s future.

How do we generate the price momentum score of vTv Therapeutics Inc?

When generating the price momentum score for vTv Therapeutics Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of vTv Therapeutics Inc’s prices. A higher score indicates a more stable short-term price trend for vTv Therapeutics Inc.

How do we generate the institutional confidence score of vTv Therapeutics Inc?

To generate the institutional confidence score of vTv Therapeutics Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about vTv Therapeutics Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of vTv Therapeutics Inc.

How do we generate the risk management score of vTv Therapeutics Inc?

To assess the risk management score of vTv Therapeutics Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of vTv Therapeutics Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of vTv Therapeutics Inc.